Catalog No.
DHJ31003
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Mucin-16, CA-125, Ovarian carcinoma antigen CA125, CA125, MUC-16, Ovarian cancer-related tumor marker CA125, MUC16
Concentration
1.36 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8WXI7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MAB-B43.13, oregovamab, CAS: 213327-37-8
Clone ID
Oregovomab
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study, PMID: 31916979
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer, PMID: 33423551
Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13, PMID: 17073521
Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab, PMID: 15268682
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer, PMID: 19075271
Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients, PMID: 31897661
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma, PMID: 31513018
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer, PMID: 15337799
Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients, PMID: 32219502
CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients, PMID: 15297171
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer, PMID: 16343178
The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer, PMID: 19307994
CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer, PMID: 18481390
Antibody-based immunotherapy for ovarian cancer: where are we at?, PMID: 24285017
The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis, PMID: 29894066
Monoclonal antibodies in gynecological cancer: a critical point of view, PMID: 22235224
Antibody-based immunotherapy of solid cancers: progress and possibilities, PMID: 26314410
Monoclonal antibody therapy of ovarian cancer, PMID: 15757441
Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy, PMID: 26527287
Gateways to clinical trials, PMID: 17344945
Molecular/genetic therapies in ovarian cancer: future opportunities and challenges, PMID: 22343235
Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives, PMID: 26675567
The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review), PMID: 18497976
Gateways to clinical trials, PMID: 12851663
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer, PMID: 19232697
Biologic and immunologic therapies for ovarian cancer, PMID: 12743131
Gateways to clinical trials, PMID: 15319815
Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis, PMID: 31190984
Gateways to clinical trials, PMID: 16810345
Current approaches in ovarian cancer vaccines, PMID: 15729204
Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?, PMID: 23030299
Gateways to clinical trials. March 2003, PMID: 12731460
Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer, PMID: 18336400
New agents and new formulations for the treatment of ovarian cancer, PMID: 16491624
Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?, PMID: 30252883
OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells, PMID: 9085127
Development and characterization of a bispecific single-chain antibody directed against T cells and ovarian carcinoma, PMID: 10768839
Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patients, PMID: 9352556
Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model, PMID: 10211788
Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13, PMID: 7590780
The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients, PMID: 10948399
Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres, PMID: 9755874
Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo, PMID: 11471484
An antibody-lectin sandwich assay for the determination of CA125 antigen in ovarian cancer patients, PMID: 8872106
Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop, PMID: 8938947
For research use only. Not for human or drug use.
